How Percutaneous Embolization Works and What It Treats

Percutaneous embolization is a minimally invasive technique in which a doctor threads a thin catheter through the skin, navigates it into a blood vessel under image guidance, and deliberately blocks that vessel with an injected material. The blocked vessel can no longer carry blood to a tumor, a site of hemorrhage, an abnormal tangle of arteries and veins, or an organ that needs to shrink. First developed for emergency bleeding control and brain-vessel abnormalities, the procedure now spans an unexpectedly wide range of conditions, from uterine fibroids and enlarged prostates to chronic knee pain and leaking lymphatic ducts.

What Happens During the Procedure

The basic sequence is the same regardless of the target. An interventional radiologist inserts a needle into a large artery, usually in the groin or wrist, and passes a guidewire and catheter through it. Using real-time X-ray imaging (fluoroscopy), they steer the catheter through the vascular tree until its tip sits inside or just upstream of the vessel they want to block. Then they inject an embolic agent, a substance designed to plug the vessel. The whole procedure typically takes between one and three hours and is done under conscious sedation or local anesthesia rather than general anesthesia.

What varies is the embolic agent. The choice depends on whether the occlusion should be permanent or temporary, how large the target vessel is, and whether the agent also needs to deliver drugs or radiation.

The Materials That Block a Vessel

Embolic agents fall into three broad families. Mechanical devices include metallic coils and vascular plugs, which physically fill a vessel lumen and promote clot formation around themselves. Coils are the workhorse for larger arteries and have been used for decades in aneurysm treatment; newer generations include bioactive coatings and complex shapes that pack more densely.

Particulate agents are tiny spheres, often made of polyvinyl alcohol or calibrated gelatin, that lodge in smaller downstream branches. Because their size can be selected precisely, operators can target vessels of a specific diameter while leaving larger branches open. Particles are especially common in tumor embolization and fibroid treatment.

Liquid agents behave differently. One widely used product, Onyx, is an ethylene-vinyl alcohol copolymer dissolved in dimethyl sulfoxide. When it is injected into a vessel, the solvent diffuses into the surrounding blood and the polymer precipitates, forming a solid cast that conforms to the vessel’s shape.¹ Another liquid, n-butyl cyanoacrylate (a medical-grade “super glue”), polymerizes on contact with blood and is especially useful in high-flow malformations where particles would wash downstream before lodging.²

Emergency Bleeding Control

One of the most time-critical uses of percutaneous embolization is in trauma patients who are bleeding heavily from damaged pelvic arteries. Pelvic fractures from car crashes or falls can tear arteries deep inside the pelvis where direct surgical access is difficult and dangerous. Transcatheter embolization has become a first-line option at many trauma centers for this scenario because it can stop arterial hemorrhage without the need for open surgery.³ ⁴

Speed matters enormously. A study of severe pelvic fracture patients found that those who received embolization early had a mortality rate of about 6%, compared with 9% in a delayed group and 25% in those who received the procedure late.⁵ The same principle applies in pediatric trauma, where angiography and embolization have been shown to be relatively safe and effective for abdominal and pelvic bleeding.⁶

Liver Cancer Treatment

The liver is uniquely suited to embolization because of its dual blood supply. Healthy liver cells get most of their oxygen from the portal vein, while liver tumors are fed almost exclusively by hepatic arteries. This means an interventional radiologist can block arterial branches feeding a tumor without starving the surrounding normal tissue.

Transarterial chemoembolization (TACE) exploits this anatomy by delivering a high concentration of chemotherapy drugs directly into the tumor’s arterial supply and then plugging the vessel behind the drugs, trapping them in the tumor bed and cutting off its blood flow at the same time. Randomized controlled trials have shown TACE to be effective for palliative treatment of liver cancer, helping to control local tumor growth and prolong survival.⁷ ⁸

A related technique, transarterial radioembolization (TARE), replaces the chemotherapy drugs with tiny radioactive microspheres, usually loaded with yttrium-90. The microspheres lodge in the tumor’s microvasculature and deliver a high dose of radiation over a short distance, killing cancer cells while leaving surrounding liver tissue largely unaffected. The antitumor effect comes mostly from the radiation rather than from blocking blood flow.⁹ Both TACE and TARE have become standard treatment options for liver cancers that cannot be surgically removed.

Uterine Fibroids

Uterine artery embolization (UAE) has given many women a way to treat symptomatic fibroids without a hysterectomy. The procedure targets the uterine arteries that feed fibroid growth, and once those arteries are blocked, fibroids lose their blood supply and gradually shrink. One trial reported that median uterine volume dropped by about 35% and the dominant fibroid shrank by roughly 42% after treatment, with significant improvements in heavy periods, painful menstruation, and urinary symptoms. Over 90% of participants expressed satisfaction with the outcome.¹⁰

Another study with a year of follow-up found even larger reductions: uterine length decreased by about 56% and dominant fibroid diameter by about 52%, with heavy menstrual bleeding improving in over 90% of patients and complete fibroid infarction confirmed in over 80%.¹¹

How does UAE compare with myomectomy, the surgical alternative that also preserves the uterus? A meta-analysis found no significant difference in quality of life between the two approaches at either two or four years. However, women in the UAE group tended to have somewhat higher symptom-severity scores at those follow-up points, suggesting that while UAE improves quality of life comparably to surgery, residual symptoms may persist more often.¹² The trade-off is that UAE involves a shorter hospital stay, faster recovery, and no surgical incision.

Enlarged Prostate

Prostate artery embolization (PAE) is a newer application of the same principle for men with bothersome urinary symptoms from benign prostatic hyperplasia. By blocking the small arteries feeding the prostate, PAE reduces prostate volume, which relieves the squeeze on the urethra. A systematic review and meta-analysis found significant improvements in symptom scores, urinary flow rate, and prostate volume out to 24 months.¹³ A more recent case series confirmed those trends: at 12 months, mean symptom scores roughly halved and prostate volume fell from an average of about 66 cc to 49 cc.¹⁴ PAE is particularly attractive for men who want to avoid surgical prostate procedures or who are poor candidates for general anesthesia.

Brain Aneurysms and Arteriovenous Malformations

Neurovascular embolization may be the field where the technique has evolved the most. Coil embolization of brain aneurysms, where tiny platinum coils are packed inside the aneurysm sac to prevent rupture, began with simple helical coils and has since progressed through several generations of bioactive, expandable, and complex-shaped designs. Balloon-assisted and stent-assisted coiling now allows treatment of aneurysms with wide necks that would previously have been considered untreatable by endovascular means.¹⁵

Arteriovenous malformations (AVMs), which are abnormal tangles of arteries and veins that bypass the normal capillary bed, also respond to embolization. Liquid agents can be injected deep into these malformations through microcatheters navigated into vessels previously considered too small to access. A systematic review of AVM-associated aneurysms reported complete occlusion in about 56% of cases treated with coils and 99% of those treated with parent-vessel sacrifice, though with a complication rate of around 12%.¹⁶ For brain AVMs, embolization often serves as a first step to shrink the malformation before surgery or radiation, and the combined approach can lower the total cost per cure compared with surgery alone.¹⁷

Knee Osteoarthritis

One of the most surprising recent applications of embolization is for chronic knee pain. Genicular artery embolization (GAE) targets the tiny abnormal blood vessels that proliferate around an arthritic knee joint and are thought to carry the nerve fibers responsible for persistent pain. A meta-analysis of nine studies covering 270 patients found a technical success rate above 99%, with pain scores dropping substantially over 12 months. About 78% of patients met a clinically meaningful improvement threshold for pain, and 92% met the threshold for overall knee function.¹⁸ Another study showed median pain and function scores improving by roughly two-thirds at one year.¹⁹

A randomized controlled trial comparing GAE against a sham procedure added an important nuance: the benefit above placebo was significant only when all targeted genicular arteries were completely embolized. In the complete-embolization group, about 77% of patients reported being moderately or much better, compared with 38% in the sham group.²⁰ That means the procedure’s success depends heavily on technical completeness, and incomplete treatments may not outperform placebo.

Less Common but Growing Applications

Percutaneous embolization keeps spreading into new territories. Thoracic duct embolization treats chylothorax, a condition in which lymphatic fluid leaks into the chest cavity, often after cardiothoracic surgery. A catheter is threaded into the lymphatic system through an abdominal access point and the leaking duct is sealed with glue or coils. Early prospective data showed the technique to be safe and curative in patients with a demonstrable duct leak, offering an alternative to surgical ligation.²¹ ²²

Peripheral vascular malformations, both fast-flow and slow-flow types, are treated effectively with percutaneous sclerotherapy and endovascular embolization as first-line interventions.²³ For slow-flow malformations such as venous and large-cyst lymphatic malformations, serial sclerotherapy produces good to excellent results in roughly 75% to 90% of patients.²⁴

Portal vein embolization follows a different logic entirely. Rather than treating a disease directly, it is used before major liver surgery. By blocking portal vein branches that supply the part of the liver scheduled for removal, surgeons force the remaining liver to grow larger over several weeks, so that enough functional liver remains after the operation.

Post-Embolization Syndrome and Other Complications

The most common side effect after any embolization that blocks a substantial amount of tissue is post-embolization syndrome (PES). It typically shows up within a day or three of the procedure and involves some combination of fever, nausea, abdominal pain, and temporarily elevated liver enzymes.²⁵ PES is essentially the body’s inflammatory response to tissue that has just lost its blood supply. It is uncomfortable but usually self-limiting. A meta-analysis found that giving a steroid (dexamethasone) before the procedure significantly cut the rates of abdominal pain, fever, and nausea after liver chemoembolization.²⁶

A more serious concern is non-target embolization, when embolic material drifts into a vessel that was not meant to be blocked. The consequences depend on what that vessel supplies. In prostate embolization, for instance, one documented case involved microspheres refluxing into an unprotected artery and causing a penile ulcer.²⁷ In knee embolization, the most common adverse event is transient skin discoloration, occurring in roughly 12% of patients. Researchers have found that applying periarticular cooling during the procedure can reduce the area of non-target perfusion by about 74%, which in turn reduces skin changes afterward.²⁸

The Angiogenesis Rebound in Tumor Embolization

One biological wrinkle that matters most in cancer treatment is that cutting off a tumor’s blood supply does not simply kill it quietly. The sudden oxygen deprivation triggers a hypoxic stress response in surviving cancer cells. An animal study showed that after transarterial embolization, levels of a key oxygen-sensing protein (HIF-1alpha) nearly tripled in the treated tumors, rising from about 23% of cells staining positive before the procedure to 60% afterward.²⁹ That protein in turn activates signals that promote new blood-vessel growth around the tumor.³⁰

This angiogenic rebound is one reason embolization for liver cancer is often repeated in multiple sessions and combined with systemic therapies. It is also a driving force behind the development of drug-eluting beads, which release chemotherapy directly at the embolization site to kill tumor cells that survive the initial blood-supply cutoff.

Imaging Technology That Guides the Catheter

Accurate catheter placement is what separates a successful embolization from a complication. Traditional fluoroscopy and digital subtraction angiography remain the backbone, but cone-beam CT, which produces three-dimensional cross-sectional images right in the angiography suite, has become an increasingly important add-on. In emergency embolization cases, automatic vessel-detection software paired with cone-beam CT achieved a 95% technical success rate for guiding a microcatheter to the correct bleeding site.³¹

For liver tumor embolization specifically, dual-phase cone-beam CT detected tumors in 100% of cases compared with 83% for standard angiography, and it enabled a higher proportion of super-selective embolizations (targeting only the tiny artery feeding the individual tumor) while actually shortening fluoroscopy time.³² Better imaging translates directly into less embolic material landing where it should not, which is the primary mechanism by which non-target embolization is avoided.

Bioresorbable and “Smart” Embolic Materials

The embolic agents described above are mostly permanent. Coils stay in the vessel forever; Onyx casts remain as inert plugs. For some applications, that permanence is ideal, but for others, a material that blocks a vessel temporarily and then dissolves would be preferable. Researchers have produced biodegradable hydrogel microspheres from natural polymers like carboxymethyl cellulose and chitosan that degrade over a window of about two weeks to a month, depending on their composition.³³

Beyond simple biodegradability, newer hydrogel platforms are being designed to respond to their environment. Some can release drugs in response to the acidic conditions inside a tumor, others incorporate materials that allow real-time imaging feedback so the operator can see where the gel has settled, and still others are being engineered with shape-memory properties that allow them to expand after injection.³⁴ ³⁵ Most of these materials remain in preclinical or early clinical stages, but they point toward a future where embolization is not just a mechanical plug but a programmable, self-dissolving drug-delivery platform tailored to the disease being treated.